Management of anemia in patients receiving triple therapy for hepatitis C

Affiliations

A Sidney Barritt 4th. Gastroenterol Hepatol (N Y). 2013 May.

. 2013 May;9(5):314-6.

¹ Assistant Professor of Medicine University of North Carolina at Chapel Hill Chapel Hill, North Carolina.

No abstract available

References

1. Barritt AS, IV, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for HCV. Gastroenterology. 2012;142:1314–1323-e1.. - PMC - PubMed
1. Hitomi Y, Cirulli ET, Fellay J, et al. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology. 2011;140:1314–1321. - PubMed
1. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705–716. - PubMed
1. Mancino P, Falasca K, Ucciferri C, Pizzigallo E, Vecchiet J. Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis. MediterrJHematolInfect Dis. 2010;2 e2010003. - PMC - PubMed
1. Thompson AJ, Santoro R, Piazzolla V, et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hematology. 2011;53:389–395. - PMC - PubMed